Skip to content

Multi-center, Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy

This study will look at whether an investigational drug, called Ampreloxetine, works and how safe it is when taken over several months to treat symptomatic Neurogenic orthostatic hypotension in people with multiple system atrophy (MSA). It will also look at the effects of Ampreloxetine on general well-being and if it can improve symptoms of Neurogenic orthostatic hypotension.

null

Participation Requirements

  • Sex:

    Male, Female, Intersex

  • Eligible Ages:

    30 and up

Participation Criteria

Inclusion Criteria:
• Are at least 30 years of age
• Have symptoms related to Neurogenic orthostatic hypotension
• Have MSA

Study Location

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contact Study Team

Study Sponsored By
University of Calgary
Participants Required
More Information
Study ID: REB23-0953